A Phase  I Placebo-Controlled Trial Comparing the Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride Administration on Respiratory Drive

ConclusionsBBF did not significantly reduce respiratory drive at any dose compared with placebo, including at the maximum available prescription dose of 900  μg. Administration of oxycodone resulted in a significant dose-dependent decrease in respiratory drive. These data suggest that BBF may be a safer treatment option than full μ-opioid receptor agonists for patients with chronic pain.Trial RegistrationClinicalTrials.gov identifier, NCT03996694.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research